Apellis Pharmaceuticals
APLS
APLS
281 hedge funds and large institutions have $7B invested in Apellis Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 79 increasing their positions, 108 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.91% more ownership
Funds ownership: 96.75% → 98.66% (+1.9%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
27% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 108
Holders
281
Holding in Top 10
9
Calls
$379M
Puts
$133M
Top Buyers
| 1 | +$274M | |
| 2 | +$76.5M | |
| 3 | +$67.1M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.5M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$36.5M |
Top Sellers
| 1 | -$82.3M | |
| 2 | -$78.7M | |
| 3 | -$33.5M | |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$29.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$20.9M |